Toyama, Tadashi

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 330

Glycoprotein Hyposialylation Gives Rise to a Nephrotic-Like Syndrome That Is Prevented by Sialic Acid Administration in GNE V572L Point-Mutant Mice

Ito, M., Sugihara, K., Asaka, T., Toyama, T., Yoshihara, T., Furuichi, K., Wada, T., & Asano, M. (2012) · PLoS ONE

Glycosylation and Glycoproteins ResearchRenal Diseases and Glomerulopathies

Cited by 47

Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients

Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews

Diabetes Treatment and ManagementRenal Transplantation Outcomes and Treatments

Cited by 30

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12